XML 29 R19.htm IDEA: XBRL DOCUMENT v3.24.3
Revenue Recognition (Tables)
 9 Months Ended
Sep. 30, 2024
Revenue from Contract with Customer [Abstract]  
Schedule of Revenue by Service Line
Revenue by Service Line
Three Months Ended September 30,
(in thousands)20242023
Biologics and drug delivery
Disposable products$2,062 $455 
Services and license fees2,369 3,032 
Subtotal – Biologics and drug delivery revenue4,431 3,487 
Neurosurgery navigation and therapy
Disposable products2,860 1,874 
Services— 44 
Subtotal – Neurosurgery navigation and therapy
2,860 1,918 
Capital equipment and software
Systems and software products552 81 
Services279 276 
Subtotal – Capital equipment and software revenue831 357 
Total revenue$8,122 $5,762 
Nine Months Ended September 30,
(in thousands)
2024
2023
Biologics and drug delivery
Disposable products$4,286 $1,395 
Services and license fees8,779 8,136 
Subtotal – Biologics and drug delivery revenue13,065 9,531 
Neurosurgery navigation and therapy
Disposable products7,373 5,550 
Services— 930 
Subtotal – Neurosurgery navigation and therapy
7,373 6,480 
Capital equipment and software
Systems and software products2,394 432 
Services787 702 
Subtotal – Capital equipment and software revenue3,181 1,134 
Total revenue$23,619 $17,145 
Schedule of Other Current Assets
September 30, 2024
December 31, 2023
(in thousands)
Accounts receivable, net$3,875 $3,211 
Other contract assets
Unbilled receivables$662 $733 
Schedule of Revenue Recognized by Contract Liability The unearned portion of all such fees is classified as deferred revenue.
September 30, 2024
December 31, 2023
(in thousands)
Deferred revenues$1,732 $3,154